Summary

The Global Hepatitis Delta Virus (HDV) infection market is expected to reach USD 68.24 million by 2031 from USD 47.35 million in 2023, growing with a CAGR of 4.8% in the forecast period of 2024 to 2031.

Market Segmentation:
Global Hepatitis Delta Virus (HDV) Infection Market, By Type (Acute Hepatitis D and Chronic Hepatitis D), Treatment (Surgery (Liver Transplant) and Medication), Drug Type (Branded and Generic), Route of Administration (Oral and Parenteral), Age Group (Adults, Geriatric, and Pediatric), Gender (Female and Male), Transmission (Contaminated Needles, Exposure to Infected Blood, Blood and Plasma Product Transfusion, and Others), End User (Hospitals, Specialty Clinics, Home Care Setting, Research Institutes and Academic Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Denmark, Sweden, Norway, Poland, Austria, Finland, Portugal, Greece, Iceland, Rest of Europe, Japan, China, India, South Korea, Rest of Asia-Pacific, Brazil, Rest of South America, South Africa, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031

Overview of Global Hepatitis Delta Virus (HDV) Infection Market Dynamics:

Driver
• Increasing prevalence of hepatitis
Restraint

• High cost of treatment
Opportunity

• Rising innovative drug development
Market Players:

The key market players operating in the global Hepatitis Delta Virus (HDV) infection market are listed below:

• Gilead Sciences Inc. (U.S.)
• Genentech Inc. (U.S.)
• Alnylam Pharmaceuticals Inc. (U.S.)
• Assembly Biosciences Inc. (U.S.)
• Eiger Pharmaceuticals (U.S.)
• GlobeImmune Inc. (U.S.)
• Huahui Health Ltd. (China)
• Johnson & Johnson Services Inc. (U.S.)
• PharmaEssentia Corporation (Taiwan)
• Replicor (Canada)
• Vir Biotechnology Inc. (U.S.)

ページTOPに戻る

Table of Contents

1 INTRODUCTION 46
1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET 46
1.4 CURRENCY AND PRICING 48
1.5 LIMITATIONS 48
1.6 MARKETS COVERED 48
2 MARKET SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 DBMR TRIPOD DATA VALIDATION MODEL 54
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 57
2.6 MULTIVARIATE MODELLING 58
2.7 MARKET END USER COVERAGE GRID 59
2.8 DBMR MARKET POSITION GRID 60
2.9 VENDOR SHARE ANALYSIS 61
2.10 SECONDARY SOURCES 62
2.11 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 67
4.1 PESTAL ANALYSIS 70
4.2 PORTER FIVE FORCES 71
4.3 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET 72
4.4 DISTRIBUTION OF PRODUCTS BY PHASE 79
5 EPIDEMIOLOGY 80
6 MARKET OVERVIEW 83
6.1 DRIVERS 85
6.1.1 GROWING PREVALENCE OF HEPATITIS 85
6.1.2 INCREASE IN HEALTHCARE EXPENDITURE 86
6.1.3 ONGOING RESEARCH AND DEVELOPMENT INITIATIVES 86
6.1.4 ADVANCES IN DIAGNOSTIC TECHNOLOGIES 87
6.2 RESTRAINTS 89
6.2.1 LIMITED AWARENESS OF HEPATITIS DELTA VIRUS (HDV) 89
6.2.2 HIGH COST OF TREATMENT 89
6.3 OPPORTUNITIES 91
6.3.1 RISING INNOVATIVE DRUG DEVELOPMENT 91
6.3.2 INCREASING DEVELOPMENT OF COMBINATION THERAPIES 93
6.3.3 GROWING ADVANCEMENTS IN DIGITAL HEALTH SOLUTIONS 94
6.4 CHALLENGES 95
6.4.1 SIDE EFFECTS OF CURRENT TREATMENTS 95
6.4.2 SLOW REGULATORY APPROVALS 96
7 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE 97
7.1 OVERVIEW 98
7.2 ACUTE HEPATITIS D 101
7.3 CHRONIC HEPATITIS D 101
8 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT 102
8.1 OVERVIEW 103
8.2 SURGERY (LIVER TRANSPLANT) 106
8.3 MEDICATION 106
8.3.1 APPROVED THERAPIES 107
8.3.1.1 PEGYLATED INTERFERON ALPHA 107
8.3.1.2 ENTRY INHIBITOR (BULEVIRTIDE) 107
8.3.2 EMERGING THERAPIES 107
9 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM 108
9.1 OVERVIEW 109
9.2 TABLET 112
9.3 CAPSULE 112
9.4 INJECTABLE 113
10 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE 114
10.1 OVERVIEW 115
10.2 BRANDED 118
10.3 GENERIC 118
11 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION 119
11.1 OVERVIEW 120
11.2 ORAL 123
11.2.1 TABLET 123
11.2.2 CAPSULE 123
11.2.3 OTHERS 123
11.3 PARENTERAL 124
12 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER 125
12.1 OVERVIEW 126
12.2 FEMALE 129
12.3 MALE 129
13 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP 130
13.1 OVERVIEW 131
13.2 ADULTS 134
13.3 GERIATRIC 134
13.4 PEDIATRIC 135
14 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION 136
14.1 OVERVIEW 137
14.2 CONTAMINATED NEEDLES 140
14.3 EXPOSURE TO INFECTED BLOOD 140
14.4 BLOOD AND PLASMA PRODUCT TRANSFUSION 141
14.5 OTHERS 141
15 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER 142
15.1 OVERVIEW 143
15.2 HOSPITALS 146
15.3 SPECIALTY CENTERS 146
15.4 HOME CARE SETTING 147
15.5 RESEARCH INSTITUTES & ACADEMIC CENTERS 147
15.6 AMBULATORY SURGICAL CENTERS 148
15.7 OTHERS 148
16 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL 149
16.1 OVERVIEW 150
16.2 DIRECT TENDER 153
16.3 RETAIL SALES 153
16.3.1 HOSPITAL PHARMACY 154
16.3.2 RETAIL PHARMACY 154
16.3.3 ONLINE PHARMACY 154
16.4 OTHERS 154
17 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION 155
17.1 OVERVIEW 156
17.2 EUROPE 160
17.2.1 GERMANY 165
17.2.2 FRANCE 169
17.2.3 U.K 173
17.2.4 ITALY 177
17.2.5 SPAIN 181
17.2.6 NETHERLANDS 185
17.2.7 SWITZERLAND 189
17.2.8 RUSSIA 193
17.2.9 BELGIUM 197
17.2.10 TURKEY 201
17.2.11 DENMARK 205
17.2.12 SWEDEN 209
17.2.13 POLAND 213
17.2.14 NORWAY 217
17.2.15 FINLAND 221
17.2.16 REST OF EUROPE 225
17.3 MIDDLE EAST AND AFRICA 226
17.4 NORTH AMERICA 264
17.4.1 U.S. 268
17.4.2 CANADA 272
17.4.3 MEXICO 276
17.5 ASIA PACIFIC 280
17.6 SOUTH AMERICA 338
18 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY LANDSCAPE 352
18.1 COMPANY SHARE ANALYSIS: GLOBAL 352
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 353
18.3 COMPANY SHARE ANALYSIS: EUROPE 354
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 355
19 SWOT ANALYSIS 356
20 COMPANY PROFILE 357
20.1 GILEAD SCIENCES, INC. 357
20.1.1 COMPANY SNAPSHOT 357
20.1.2 REVENUE ANALYSIS 358
20.1.3 COMPANY SHARE ANALYSIS 358
20.1.4 PIPELINE PRODUCT 359
20.1.5 RECENT DEVELOPMENTS 359
20.2 GENENTECH, INC. 361
20.2.1 COMPANY SNAPSHOT 361
20.2.2 PRODUCT PORTFOLIO 361
20.2.3 RECENT DEVELOPMENT 361
20.3 ALNYLAM PHARMACEUTICALS, INC. 362
20.3.1 COMPANY SNAPSHOT 362
20.3.2 REVENUE ANALYSIS 362
20.3.3 PIPELINE PRODUCT 363
20.3.4 RECENT DEVELOPMENTS 363
20.4 ASSEMBLY BIOSCIENCES, INC. 364
20.4.1 COMPANY SNAPSHOT 364
20.4.2 REVENUE ANALYSIS 364
20.4.3 PIPELINE PRODUCT 365
20.4.4 RECENT DEVELOPMENTS 365
20.5 EIGER BIOPHARMACEUTICALS 366
20.5.1 COMPANY SNAPSHOT 366
20.5.2 REVENUE ANALYSIS 366
20.5.3 COMPANY SHARE ANALYSIS 367
20.5.4 PRODUCT PORTFOLIO 367
20.5.5 PIPELINE PRODUCT 367
20.5.6 RECENT DEVELOPMENT 368
20.6 GLOBEIMMUNE INC. 369
20.6.1 COMPANY SNAPSHOT 369
20.6.2 PIPELINE PRODUCT 369
20.6.3 RECENT DEVELOPMENT 369
20.7 HUAHUI HEALTH LTD. 370
20.7.1 COMPANY SNAPSHOT 370
20.7.2 PIPELINE PRODUCT 370
20.7.3 RECENT DEVELOPMENT 370
20.8 JOHNSON & JOHNSON SERVICES, INC. 371
20.8.1 COMPANY SNAPSHOT 371
20.8.2 REVENUE ANALYSIS 371
20.8.3 PIPELINE PRODUCT 372
20.8.4 RECENT DEVELOPMENT 372
20.9 PHARMAESSENTIA CORPORATION 373
20.9.1 COMPANY SNAPSHOT 373
20.9.2 REVENUE ANALYSIS 373
20.9.3 PIPELINE PRODUCT 374
20.9.4 RECENT DEVELOPMENT 374
20.10 REPLICOR 375
20.10.1 COMPANY SNAPSHOT 375
20.10.2 PIPELINE PRODUCT 375
20.10.3 RECENT DEVELOPMENTS 376
20.11 VIR BIOTECHNOLOGY, INC. 377
20.11.1 COMPANY SNAPSHOT 377
20.11.2 REVENUE ANALAYSIS 377
20.11.3 PRODUCT PIPELINE 378
20.11.4 RECENT DEVELOPMENTS 378
21 QUESTIONNAIRE 379
22 RELATED REPORTS 383